Centrient Pharmaceuticals

Centrient Pharmaceuticals, a pharmaceutical preparation manufacturer headquartered in the Netherlands, reported total greenhouse gas (GHG) emissions of approximately 601.8 million kg CO2e for the year 2025. This figure encompasses Scope 1, 2, and 3 emissions.

Breaking down these emissions, Scope 1 accounted for about 101.5 million kg CO2e, with stationary combustion being the largest contributor. Scope 2 emissions, using the market-based method, were approximately 148.0 million kg CO2e, primarily from purchased electricity. Scope 3 emissions were the most significant, totalling approximately 352.3 million kg CO2e, with purchased goods and services being the largest category.

For 2024, Centrient Pharmaceuticals reported total GHG emissions of approximately 697.0 million kg CO2e. Scope 1 emissions were around 142.9 million kg CO2e, while Scope 2 market-based emissions were approximately 118.1 million kg CO2e. Scope 3 emissions were the largest component at approximately 436.1 million kg CO2e, driven by purchased goods and services.

In 2023, the company's total GHG emissions were approximately 733.0 million kg CO2e. Scope 1 emissions were around 143.3 million kg CO2e, and Scope 2 market-based emissions were approximately 141.4 million kg CO2e. Scope 3 emissions constituted approximately 448.2 million kg CO2e, with purchased goods and services being the dominant factor.

Centrient Pharmaceuticals has established several ambitious climate commitments. They aim for an absolute reduction in Scope 1 and 2 GHG emissions of 46.2% by 2031, using 2022 as the baseline year. This target is aligned with keeping global warming to 1.5°C. Furthermore, the company commits to reducing absolute Scope 3 GHG emissions from purchased goods and services and fuel and energy-related activities by 27.5% within the same timeframe. The company also previously had a near-term target to reduce carbon emission intensity by 35% by 2025 and 50% by 2030, based on a 2015 baseline year.